| |
|
|
|
Hilton Boston Back Bay, Boston, MA
August 13-15, 2013
Session Titles: - The Promise of T Cell Engineering
- It Takes Two to Tango: Fine Tuning of Tumor Cells and T Lymphocytes for Maximized Anti-Tumor Activity
- Improved Cancer Immunotherapy through CD134 plus CD137 Dual Co-Stimulation
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- Advances in Biomarker Validation and Trial Design for Antitumor Immunotherapy
- Exploring Synergy between Targeted Therapy and Immunotherapy
- Synergism Between Anti-Tumor Antibodies and PK-Extended IL-2
- Identifying New Cancer Immunotherapy Targets for T Cells
- Immunomodulatory Antibody-Fusion Proteins for Cancer Immunotherapy
- TIM (T Cell Immunoglobulin and Mucin)-3 as a Potential Target for Cancer Immunotherapy
- Allovectin: In vivo Studies and Potential Synergy with other Advanced Melanoma Immunotherapeutics
- Clinical Update of IL2 Adjunctive Co-Therapy for Suppression of Solid Tumors with Designer T Cells
- Challenges in Vaccine Therapy for Hematological Malignancies
- Biomarkers Correlative of Clinical Response to Sipuleucel-T
- Partnering Therapeutic Vaccines with Large Pharma
- Clinical Results of Pexa-Vec (JX-594): Multi-Mechanistic Oncolytic Viruses as a Strategy for Cancer Immunotherapy
- Clinical Update on PROSTVAC, a Therapeutic Vaccine Candidate for Advanced Prostate Cancer
- Immune Monitoring on Pre-Surgical Clinical Trials with a Novel Checkpoint Blockade Agent, Anti-CTLA-4
- Preliminary Clinical Efficacy and Safety of MK-3475 (Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Melanoma
- Development of Immunomodulatory PD-1 Antibodies in Renal Cell Carcinoma
- Anti-PD-1 Antibody Therapy for B-Cell Lymphoma
- AMP-224, A Fusion Protein with Potential to Modulate the PD-1 Pathway
- Immunocytokines: A Novel Potent Class of Armed Antibodies
- Mechanism of Action and Progress Update for MGA271: An Fc-Enhanced mAb Targeting B7-H3 in Solid Tumors
- Preclinical Update: Development of a Human Anti-CD27 Monoclonal Antibody as a Potential Cancer Therapy
- Targeting CD47-SIRPa Interactions for Potentiating Antibody Therapy in Cancer
- Clinical Trials Design for Cancer Immune Therapies
- Characteristics and Management of Immune-Related Adverse Effects Associated with Ipilimumab, a New Immunotherapy for Metastatic Melanoma
- Safety Challenges to Development of Immune System Activating Antibodies
- MCLA-117: ABiclonics – ENGAGE Bispecific IgG Product Lead Targeting CLEC12A and CD3 in AML
- Bispecific Antibody Targeting CD47 Aiming at Increasing Phagocytosis of Cancer Cells
|
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute |
|
|
Invited Speakers:
|
|
- Adam J. Adler, Ph.D., Associate Professor of Immunology, University of Connecticut
- Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering & Gene Transfer and Gene Expression Laboratory, Memorial Sloan-Kettering Cancer Center
- Daniel J. Powell, Jr., M.D., Assistant Professor, Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
- Rakesh K. Jain, Ph.D., Andrew Werk Cook Professor of Tumor Biology, Harvard Medical School; Director, E.L. Steele Laboratory of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital
- Susan R. Slovin, M.D., Ph.D., Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan–Kettering Cancer Center
- Zachary Cooper, Ph.D., Postdoctoral Research Associate, Surgical Oncology, Massachusetts General Hospital
- John Doukas, Ph.D., Senior Director, Preclinical Safety and Efficacy, Vical, Inc.
- K. Dane Wittrup, Ph.D., Dubbs Professor, Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Robert Holt, Ph.D., Senior Scientist and Head of Sequencing, British Columbia Cancer Agency, Canada
- Dafne Müller, Ph.D., Researcher, Institute of Cell Biology and Immunology, University of Stuttgart, Germany
- Ana Carrizosa Anderson, Ph.D., Assistant Professor, Neurology, Harvard Medical School
- Richard P. Junghans, M.D., Professor, Department of Medicine, Boston University School of Medicine; Roger Williams Medical Center
- Anne Moon, Ph.D., Vice President, Product Development, Jennerex
- David E. Avigan, M.D., Associate Professor, Medicine, Harvard Medical School; Director, Hematologic Malignancy/Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center
- James Trager, Ph.D., Vice President, Research, Dendreon
- Kevin Heller, Global Lead Oncology; Search, Evaluation and Diligence, Bristol-Myers Squibb
- Alain Delcayre, Ph.D., Vice President, R&D, BN Immunotherapeutics
- Padmanee Sharma, M.D., Associate Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Omid Hamid, M.D., Director, Melanoma Center, Angeles Clinic and Research Institute
- Lauren Harshman, M.D., Assistant Professor, Dana-Farber Cancer Institute
- Sattva S. Neelapu, M.D., Associate Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- Solomon Langermann, Ph.D., CSO, Amplimmune
- Lawrence J. Thomas, Ph.D., DABT, CMAR, Senior Director, Preclinical Research and Development, Celldex Therapeutics, Inc.
- Catherine Hutchinson, Ph.D., Research Scientist, Philochem, Switzerland
- Paul Moore, Ph.D., Vice President, Cell Biology & Immunology, Macrogenics
- Timo van den Berg, Ph.D., Head, Blood Cell Research, Sanquin Blood Supply Foundation, The Netherlands
- Lex Bakker, Ph.D., Chief Development Officer, Merus, The Netherlands
- Harriet Kluger M.D., Associate Professor, Yale Cancer Center
- Stephanie Andrews, Oncology Nurse Practitioner, Moffitt Cancer Center
- Rakesh Dixit, Ph.D., DABT, Vice President, Research & Development, Global Head, Biologics Safety Assessment, Pathology & LAR, MedImmune (AstraZeneca Biologics)
- Krzysztof Masternak, Ph.D., Head of Biology, Novimmune SA, Switzerland
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
July 19, 2013
|
|
|
|
|
|
|
|
Registration:
|
|
Register Now
|
|
|
E-mail:
|
|
kwaterman@healthtech.com
|
|
|
|
|
|
|
|
|